Evidence map›Paper›PMID 33201353›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2021

Ten-year changes in visual acuity at baseline and at 2 years after treatment in a Japanese population with age-related macular degeneration.

Tomoko Sawada, Tsutomu Yasukawa, Hiroko Imaizumi, Hisashi Matsubara, Kazuhiro Kimura, Hiroto Terasaki, Hiroto Ishikawa, Tomoya Murakami, Masaru Takeuchi, Yoshinori Mitamura and 6 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 14 institutions in 1 country.

Tomoko SawadaDepartment of Ophthalmology, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Shiga, 520-2192, Japan. tsawada@belle.shiga-med.ac.jp.ORCID http://orcid.org/0000-0002-9828-4288
Tsutomu YasukawaDepartment of Ophthalmology, Nagoya City University, Nagoya, Japan.
Hiroko ImaizumiDepartment of Ophthalmology, Sapporo City General Hospital, Sapporo, Japan.
Hisashi MatsubaraDepartment of Ophthalmology, Mie University, Tsu, Japan.
Kazuhiro KimuraDepartment of Ophthalmology, Yamaguchi University, Ube, Japan.
Hiroto TerasakiDepartment of Ophthalmology, Kagoshima University, Kagoshima, Japan.
Hiroto IshikawaDepartment of Ophthalmology, Hyogo College of Medicine, Nishinomiya, Japan.
Tomoya MurakamiDepartment of Ophthalmology, University of Tsukuba, Tsukuba, Japan.
Masaru TakeuchiDepartment of Ophthalmology, National Defense Medical College, Tokorozawa, Japan.
Yoshinori MitamuraDepartment of Ophthalmology, Tokushima University, Tokushima, Japan.
Mariko YamashitaDepartment of Ophthalmology, Nara Medical University, Kashihara, Japan.
Yoshihiro TakamuraDepartment of Ophthalmology, University of Fukui, Yoshida-gun, Japan.
Toshinori MurataDepartment of Ophthalmology, Shinshu University, Matsumoto, Japan.
Jiro KogoDepartment of Ophthalmology, St. Marianna University School of Medicine, Kawasaki, Japan.
Masahito OhjiDepartment of Ophthalmology, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Shiga, 520-2192, Japan.
J-CREST (Japan Clinical Retinal Study Team) Study Group, Japan
Shiga University of Medical Science · JPHyogo Medical University · JPKagoshima University · JPMie University · JPNagoya City University · JPNara Medical University · JPNational Defense Medical College · JPSapporo City General Hospital · JPShinshu University · JPSt. Marianna University School of Medicine · JPTokushima University · JPUniversity of Fukui · JPUniversity of Tsukuba · JPYamaguchi University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe investigated 10-year changes in baseline best-corrected visual acuity (BCVA), as well as functional and anatomical changes at 1 and 2 years after initial treatment, in eyes with treatment-naïve neovascular age-related macular degeneration (nAMD).

methodsThis retrospective, multicenter, case series reviewed patients with treatment-naïve nAMD who underwent initial treatment from 2006 to 2015, using photodynamic therapy (PDT), anti-vascular endothelial growth factor (VEGF), or a combination of PDT and anti-VEGF. BCVA and central retinal subfield thickness (CRST), were measured at baseline and at 1 or 2 years of follow-up.

resultsIn total, 3096 eyes of 3096 patients were included from 14 hospitals. Mean BCVA at baseline became significantly better over the 10-year study period (P < 0.001). BCVA at 1 year significantly improved from baseline in patients who underwent initial treatment from 2009 to 2015 (P = 0.001, 2009; P = 0.004, 2010; P = 0.01, 2011; P < 0.001, 2012-2015). BCVA at 2 years significantly improved from baseline in patients who underwent initial treatment from 2012 to 2015 (P < 0.001, 2012; P < 0.001, 2013-2015). CRST at 1 year decreased significantly from CRST at baseline, each year from 2006 to 2015 (P < 0.001, 2006-2015). CRST at 2 years decreased significantly from CRST at baseline, each year from 2006 to 2015 (P = 0.03, 2006; P < 0.001, 2007-2015).

conclusionBaseline BCVA with treatment-naïve nAMD tended to become better during the study period. BCVA at 1 year improved in the era of anti-VEGF; BCVA at 2 years improved in patients who underwent initial treatment in 2012 or later; and CRST decreased in each year during the study period.

Indexed as

Angiogenesis InhibitorsMacular DegenerationHumansIntravitreal InjectionsJapanRanibizumabRetrospective StudiesTomography, Optical CoherenceTreatment OutcomeVascular Endothelial Growth Factor AVisual AcuityAngiogenesis InhibitorsRanibizumabVascular Endothelial Growth Factor AAge-related macular degenerationAnti-vascular endothelial growth factorBaseline visual acuityJ-CREST Study groupPhotodynamic therapy

Identifiers

PMID33201353
OpenAlexW3098126541

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.